Belgrade, 5 February 2018 – Thelargestpharmaceutical company in the region, Vršac-based Hemofarm, has become the main STADA Group’s hub for the Central and Eastern European markets. By the decision of STADA’s management, Hemofarm has assumed the responsibility for the markets of Poland, Check Republic and Slovakia, thereby additionally increasing the area of its regional competence, which has so far comprised the markets of the South East Europe (BiH, Montenegro, Slovenia, Croatia, Hungary, Romania, Bulgaria, Macedonia and Albania). This promotion is, as assessed by Stada, a result of the good work of Hemofarm after assuming the leading role of the German Group in the South East Europe in 2016.

‘The new role granted to Hemofarm is a remarkable recognition of Stada for the work and the results we achieved in the previous period. This is also good news for Serbia and the entire region, particularly bearing in mind that it is rarely seen that a company operating in a non-EU member country is entrusted with managing also the markets within the EU. Our plans are ever more ambitious with the new markets. The investments will be focused on the expansion of capacities, further upgrading of product quality, research and development of medicinal products, and particularly on the work force – around 3000 diligent, high-quality, educated people currently employed with Hemofarm’, Ronald Seeliger, Chief Executive Officer of Hemofarm and Vice President of STADA Group, said.

Hemofarm became a part of the large international Cinven and Bain Capital family through Stada in 2017. Apart from being the regional leader, the medicines with Hemofarm’s brand can also be found in pharmacies in 38 countries on three continents. Hemofarm’s state-of-the-art factories, complying with the highest international pharmaceutical standards, are located in Serbia, Montenegro and BiH – Republika Srpska, and the plants are among the top 20 percent of the most energy efficient ones in the world. Thus, apart from playing the mentioned leading role in production, Hemofarm has also assumed the role of the promoter of sustainable development and responsible operation in the region.